Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 11.12.2025 FEUZ IE00B8X9NY41 1,099,800.00 EUR 61,916,382.28 56.298  ...

LONDON--(BUSINESS WIRE)--  10-December-2025 Issue: Newday Funding Master Issuer Plc SERIES 2024-2 Class F 144A XS2834469483 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 17-November-2025 Date To: 15-December-2025 Record Date: 12-December-2025 Value Date: 15-December-2025 Benchmark Rate: 3.97571374% Margin: 4.9% Total Rate: 8.87571374% Number of Days: 28 Day Count: Actual / 365L Interest Frequency: Mont...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Emerging Markets AlphaDEX UCITS ETF 11.12.2025 FEM IE00B8X9NX34 350,002.00 USD 14,447,111.27 41.277  ...

NEW YORK--(BUSINESS WIRE)--Tharimmune, Inc. (NASDAQ: THAR) (“Tharimmune” or the “Company”), the first publicly traded company to leverage Canton Coin (“CC”) to support the Canton Network’s ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial rep...

NEW YORK--(BUSINESS WIRE)--The Board of Directors of The Korea Fund, Inc. (the "Fund") (NYSE:KF) announced today they have declared a dividend distribution totaling $1.381724 per share, comprised of a net investment income dividend of $0.437507 per share and a spillback income dividend of $0.944217 per share. The spillback dividend represents payment of the Fund’s June 30, 2025 spillback income distribution pursuant to Section 855 of the Internal Revenue Code. The distribution will be payable o...

LONDON--(BUSINESS WIRE)--  10-December-2025 Issue: Newday Funding Master Issuer Plc SERIES 2024-2 Class F RegS XS2834469301 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 17-November-2025 Date To: 15-December-2025 Record Date: 12-December-2025 Value Date: 15-December-2025 Benchmark Rate: 3.97571% Margin: 4.9% Total Rate: 8.87571% Number of Days: 28 Day Count: Actual / 365L Interest Frequency: Monthly To...

SAN FRANCISCO--(BUSINESS WIRE)--Tools for Humanity, the technology company building for humans in the age of AI, today introduced the new World App, a super app for the AI era that brings together encrypted messaging, global financial access and anonymous proof of human. The launch includes the rollout of World Chat, expanded crossborder financial tools and enhancements to World ID. Co-founders Sam Altman and Alex Blania unveiled the new experience during a live “Unwrapped” event at the company...

DALLAS--(BUSINESS WIRE)--Flowserve Corporation (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, announced that its Board of Directors has authorized a quarterly cash dividend of $0.21 per share on the Company’s outstanding shares of common stock. The dividend is payable on January 9, 2026, to shareholders of record as of the close of business on December 26, 2025. While Flowserve currently intends to pay regular quarterly cash dividend...

LONDON--(BUSINESS WIRE)--  10-December-2025 Issue: Newday Funding Master Issuer Plc SERIES 2024-2 Class E RegS XS2834468832 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 17-November-2025 Date To: 15-December-2025 Record Date: 12-December-2025 Value Date: 15-December-2025 Benchmark Rate: 3.97571% Margin: 3.9% Total Rate: 7.87571% Number of Days: 28 Day Count: Actual / 365L Interest Frequency: Monthly To...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver the same efficacy and safety profile of DAYBUE oral solution, while offering children and adults living...